Evidence map›Paper›PMID 42536057›Full record

Observational studyJMIR cancer2026

Factors Associated With the Use of the Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology (LETSGO) mHealth App in Routine Follow-Up After Gynecologic Cancer Treatment: Observational Study.

Zaklina Tarabar, Elin Børøsund, Sindre H Fosstveit, Sveinung Berntsen, Milada Hagen, Ingvild Vistad

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in JMIR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zaklina TarabarHospital of Southern Norway, Egsveien 100, Kristiansand, Agder, 4615, Norway, 47 91840889.ORCID http://orcid.org/0009-0004-3267-1113
Elin BørøsundDepartment of Digital Health Research, Division of Medicine, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0003-3897-7055
Sindre H FosstveitDepartment of Sport Science and Physical Education, University of Agder, Kristiansand, Agder, Norway.ORCID http://orcid.org/0009-0003-7815-4915
Sveinung BerntsenDepartment of Sport Science and Physical Education, University of Agder, Kristiansand, Agder, Norway.ORCID http://orcid.org/0000-0002-8250-4768
Milada HagenDepartment of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway.ORCID http://orcid.org/0000-0001-8947-8649
Ingvild VistadInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-5262-6326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mobile health (mHealth) apps offer new opportunities to support cancer survivors in managing their health, adopting healthier lifestyles, and increasing awareness of recurrence symptoms. However, despite their potential, little is known about survivors' use of such tools in routine follow-up care, or which factors are associated with their engagement. Objective: The aim of the present study was to identify survivor characteristics associated with the use of the Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology (LETSGO) app. In addition, we aimed to describe engagement patterns among gynecologic cancer survivors during the first year of follow-up after treatment. Methods: App data from 378 participants in the intervention group of the LETSGO multicenter clinical trial were included in the analysis. Using multiple logistic regression, we analyzed app data from the first year of LETSGO app use to identify participant characteristics associated with use. In addition, we described the frequency of user interactions with app features and identified the most frequently used features during the first year of the intervention in a subset of 49 participants with complete app log data. Results: Of the 378 participants in the intervention group, 267 (70.6%) used the LETSGO app at least twice and were defined as app users. The median age of app users was 63 (53-70) years vs 70 (60-78) years among app nonusers (P<.001). App use was associated with younger age (odds ratio [OR] 0.96 per year, 95% CI 0.93-0.99; P=.003), higher education (OR 2.2, 95% CI 1.1-4.6; P=.03), and having ovarian cancer (OR 2.9; 95% CI 1.1-7.5; P=.03). The LETSGO app included a monthly reminder for symptom self-registration, and monthly peaks in the symptom monitoring feature corresponded with the timing of this reminder. App log data from the full first year of the intervention were available for 49 participants. Among these, user engagement was highest for the physical activity and activity goal-setting features, whereas the disease information feature showed steady but less frequent use. Conclusions: Our findings indicate that LETSGO app use was associated with survivor characteristics such as age, education level, and cancer type. Considering user characteristics when tailoring mHealth apps may support user engagement in digital follow-up care and inform the development of mHealth tools that better align with survivors' needs and preferences. Engagement with the LETSGO app during the first year of follow-up among a subset of participants with complete app log data was highest for the physical activity and activity goal-setting features. The pattern of symptom registration following reminders indicates that scheduled prompts may support regular app engagement, while steady use of the disease information feature suggests an ongoing need for accessible health information during follow-up.

Indexed as

Cancer SurvivorsGenital Neoplasms, FemaleLife StyleMobile ApplicationsAgedFemaleFollow-Up StudiesHumansMiddle AgedSurvivorshipTelemedicineapp usecancer survivorsdigital follow-up caredigital health toolsmobile health appsuser engagement.

Identifiers

PMID42536057
PMCPMC13426126

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.